November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic PDAC
Nov 9, 2024, 15:58

Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic PDAC

Arndt Vogel, Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared a recent article by Ethan B. Ludmir on X:

Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma at Journal of Clinical Oncology.”

Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial

Authors: Ethan B. Ludmir, Alexander D. Sherry, Bryan M. Fellman, Suyu Liu, Tharakeswara Bathala, Cara Haymaker, Marina N. Medina-RosalesAlexandre Reuben, Emma B. Holliday, Grace L. Smith, Sonal S. Noticewala, Sarah Nicholas, Tracy R. Price, Rachael M. Martin-Paulpeter, Luis A. Perles, Sunyoung S. Lee, Michael S. Lee, Brandon G. Smaglo, Ryan W. Huey, Jason Willis, Dan Zhao, Lorenzo Cohen, Cullen M. Taniguchi, Eugene J. KoayMatthew H.G. Katz, Robert A. Wolff, Prajnan Das, Shubham Pant, Albert C. Koong, and Chad Tang.

Metastasis-Directed Therapy

Metastasis-Directed Therapy

 

Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GICancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer. He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.

More posts featuring Arndt Vogel.